Cardiovascular effects, pharmacokinetics and cross-reactivity in digitalis glycoside immunoassays of an antidiarrheal uzara root extract

2012 ◽  
Vol 50 (10) ◽  
pp. 729-740 ◽  
Author(s):  
Sven Schmiedl ◽  
Anne Ritter ◽  
Jacek Szymanski ◽  
Frank Schneider ◽  
Thomas Plecko ◽  
...  
Keyword(s):  
Cardiovascular Effects ◽  
Cross Reactivity ◽  
Root Extract ◽  
Digitalis Glycoside

Chemokine receptor antagonists with α1-adrenergic receptor blocker activity

2021 ◽  
Vol 0 (0) ◽  
Author(s):  
Anthony J. DeSantis ◽  
Garrett A. Enten ◽  
Xianlong Gao ◽  
Matthias Majetschak
Keyword(s):  
Chemokine Receptor ◽  
Therapeutic Potential ◽  
Cardiovascular Effects ◽  
Cross Reactivity ◽  
Resistance Arteries ◽  
Receptor Antagonists ◽  
Adrenoceptor Antagonist ◽  
Adrenoceptor Blocker ◽  
Inflammatory Drugs ◽  
Ccr2 Antagonist

Abstract Objectives Chemokine receptor antagonists are being explored for their therapeutic potential in various disease processes. As the chemokine (C–C motif) receptor 2 (CCR2) antagonist RS504393 is known to compete with ligand binding to α1-adrenoceptors, we tested a panel of 10 CCR antagonists for interactions with α1-adrenoceptors to evaluate potential cardiovascular activities and side-effect profiles. Methods The PRESTO-Tango β-arrestin recruitment assay was utilized to test whether the CCR antagonists interfere with α1b-AR activation upon stimulation with phenylephrine. Pressure myography with isolated rat resistance arteries was employed to assess their effects on phenylephrine-induced vasoconstriction. The following antagonists were tested: CCR1–BX471, BX513, BI639667; CCR2–RS504393, INCB3284; CCR3–SB328437; and CCR4–AZD2098, and C021; CCR5–Maraviroc; CCR10-BI6901. The pan-α1-adrenoceptor antagonist prazosin was used as control. Results Among the CCR antagonists tested, RS504393, BX513, and C021 inhibited phenylephrine-induced β-arrestin recruitment to α1b-adrenoceptor and phenylephrine-induced vasoconstriction. While RS504393 functioned as a competitive α1-adrenoceptor blocker, BX513 and C021 functioned as noncompetitive α1-adrenoceptor antagonists in both assay systems. Furthermore, RS504393, BX513, and C021 dose-dependently dilated arteries that were fully preconstricted with phenylephrine. Conclusions Our data suggest that CCR antagonists should be screened for cross-reactivity with α1-adrenoceptors to exclude potential adverse cardiovascular effects when used as anti inflammatory drugs.

Botulinium toxin therapy: Cardiovascular effects

1997 ◽  
Vol 103 (1) ◽  
pp. 172
Author(s):  
A Attanasio
Keyword(s):  
Cardiovascular Effects

Cannabis-associated arteritis

VASA ◽  
2010 ◽  
Vol 39 (1) ◽  
pp. 43-53 ◽  
Author(s):  
Grotenhermen
Keyword(s):  
Systematic Review ◽  
Case Reports ◽  
Case Series ◽  
Cardiovascular Effects ◽  
Causative Factor ◽  
Cannabis Use ◽  
Thromboangiitis Obliterans ◽  
Pathological Features ◽  
Scientific Support ◽  
Clinical And Pathological Features

Background: To investigate the hypothesis that cases of arteritis similar to thromboangiitis obliterans (TAO) and associated with the use of cannabis were caused by cannabis or THC (dronabinol), or that cannabis use is a co-factor of TAO. Patients and methods: A systematic review on case reports and the literature on so-called cannabis arteritis, TAO, and cardiovascular effects of cannabinoids was conducted. Results: Fifteen reports with 57 cases of an arteritis associated with the use of cannabis and two additional case series of TAO, in which some patients also used cannabis, were identified. Clinical and pathological features of cannabis-associated arteritis do not differ from TAO and the major risk factor of TAO, tobacco use, was present in most, if not in all of these cases. The proposed pathophysiological mechanisms for the development of an arteritis by cannabis use are not substantiated. Conclusions: The hypothesis of cannabis being a causative factor or co-factor of TAO or an arteritis similar to TAO is not supported by the available evidence. The use of the term “cannabis arteritis” should be avoided until or unless more convincing scientific support is forthcoming.

Concomitant Clinical Sensitivity (CCS) and Cross-Reactivity

2003 ◽  
Vol 15 (01) ◽  
pp. 018-029 ◽  
Author(s):  
Harris Steinman ◽  
Steve Lee
Keyword(s):  
Cross Reactivity ◽  
Clinical Sensitivity

Triterpenoid saponins from the cytotoxic root extract of Sideroxylon foetidissimum, an endemic Yucatecan medicinal plant

Planta Medica ◽  
2008 ◽  
Vol 74 (09) ◽  
Author(s):  
A Sánchez-Medina ◽  
PC Stevenson ◽  
S Habtemariam ◽  
LM Peña-Rodríguez ◽  
O Corcoran ◽  
...  
Keyword(s):  
Medicinal Plant ◽  
Root Extract ◽  
Triterpenoid Saponins

Protective activities of the aqueous root extract of Harungana madagascariensis in acute and repeated acetaminophen hepatotoxic rats

Planta Medica ◽  
2008 ◽  
Vol 74 (09) ◽  
Author(s):  
AA Adeneye ◽  
JA Olagunju ◽  
SO Elias ◽  
OD Olatunbosun ◽  
AO Mustafa ◽  
...  
Keyword(s):  
Root Extract ◽  
Aqueous Root Extract

Inhibition of mediator release from RBL-2H3 cells and human granulocytes by the Pelargonium sidoides root extract EPs®7630

Planta Medica ◽  
2010 ◽  
Vol 76 (12) ◽  
Author(s):  
E Koch ◽  
R Augustin ◽  
C Wohn ◽  
C Erdelmeier
Keyword(s):  
Mediator Release ◽  
Root Extract ◽  
Pelargonium Sidoides ◽  
Human Granulocytes

Antihyperglycaemic and antihyperlidaemic effects of Raphia hookeri root extract on alloxan induced diabetic rats

Planta Medica ◽  
2011 ◽  
Vol 77 (12) ◽  
Author(s):  
GO Mbaka ◽  
SO Ogbonnia ◽  
AE Banjo
Keyword(s):  
Diabetic Rats ◽  
Root Extract ◽  
Raphia Hookeri
Sign in / Sign up

Export Citation Format

Share Document